ABBELIGHT

Their core work

Abbelight is a French deep-tech SME that designs and commercializes super-resolution microscopy systems, specifically based on Single Molecule Localization Microscopy (SMLM) — a technique that breaks the diffraction limit of conventional light microscopy to image biological structures at the nanometer scale. Their product line combines advanced optical hardware with proprietary algorithms and cloud/SaaS software to deliver nanoscopy as a practical, high-throughput laboratory tool rather than a research prototype. Their work under H2020 moved from algorithm development and feasibility validation to a full commercial platform for high-content, high-throughput nanoscopy screening — meaning they can process many samples rapidly at super-resolution, which is rare in the field. They serve primarily biomedical and pharmaceutical research customers who need nanoscale imaging at scale.

What they specialise in

How they've shifted over time

Abbelight's trajectory across their two H2020 projects shows a clear product maturation arc. Their first project, NanoMAPs (2017-2018), was a Phase 1 feasibility study focused on algorithmic foundations — precision localization math borrowed conceptually from GPS systems, applied to microscopy, with early cloud infrastructure thinking. By their second project, HT-SAFe (2020-2022), the focus had shifted entirely to productization and scale: high-throughput imaging, high-content screening compatibility, and SaaS delivery — all pointing to a company that had validated its core technology and was building a commercial platform. The keyword gap between early and recent periods reflects the SME instrument logic: Phase 1 proves the idea, Phase 2 builds the product.

Abbelight is moving toward making super-resolution microscopy a routine, scalable screening tool — suggesting future collaborations would most likely involve pharmaceutical screening, drug discovery platforms, or biomedical imaging infrastructure rather than fundamental optics research.

How they like to work

Abbelight has used H2020 exclusively through SME Instrument grants (Phase 1 and Phase 2), which are designed for solo company applications — they did not build external consortia and have zero recorded consortium partners in this dataset. This means they operate as self-contained technology developers rather than collaborative research partners in the traditional sense. For future consortia, they would likely join as a specialized technology provider or instrument supplier rather than a consortium architect, unless leading an innovation action built around their platform.

Abbelight has no recorded H2020 consortium partners, which is expected given the SME Instrument funding scheme they used — these grants go directly to the company without requiring consortium partners. Their network footprint within EU-funded research is therefore narrow by design, not by limitation.

What sets them apart

Abbelight occupies a rare niche: they are one of the few commercial SMEs globally that has industrialized SMLM microscopy to the point of offering it as a high-throughput, SaaS-enabled screening platform rather than a one-off research instrument. Most SMLM players are either academic groups or large instrument manufacturers — Abbelight sits between them as an agile product company. For any consortium needing a nanoscopy instrument provider or a partner that can translate super-resolution imaging into a scalable workflow, they bring both the hardware and the software stack.

Highlights from their portfolio

• HT-SAFe
  With EUR 1.2M in SME Phase 2 funding, this project represents Abbelight's full commercial platform push — making high-throughput SMLM nanoscopy viable for pharmaceutical and biomedical screening at scale.
• NanoMAPs
  A Phase 1 feasibility study that established the algorithmic and cloud architecture underpinning Abbelight's later platform, notable for its unconventional framing of microscopy localization as a GPS-precision problem.